Recruiting at 6 sites No phase Fertility Issues

Trial comparing treatments for Fertility Issues

Official title A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology

ClinicalTrials.gov ID: NCT07050537

What this study is testing

What it's testing
The study aims to find out if keeping embryos in a steady level of oxygen or changing the oxygen level over time leads to more full-term live births.
Who it's for
The study is looking for women who are planning to have an embryo transfer as part of fertility treatment.
What's involved
Participants will have their embryos grown in the lab using either a constant or a changing oxygen level, and the team will track pregnancy outcomes.
Time commitment
The study involves standard fertility treatment visits and follow-up to check for pregnancy and birth outcomes.
  • Which group you join is decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 20 to 40, women only

You may be able to join if

  • Female: age ≥20 and ≤40 years, male: age ≥20 and ≤50 years;
  • Proposed 1st or 2nd cycle of IVF or ICSI fertilization;
  • ≥ 4 transferable embryos at oocyte stage.

You likely can't join if

  • Diagnosis of abnormal uterine cavity morphology (confirmed by 3D ultrasound or hysteroscopy), including uterine malformations (mediastinal uterus...
  • Patients who are proposed to undergo IVM;
  • Patients who are proposed to undergo PGD/ PGS;
  • Patients with untreated severe hydrosalpinx (confirmed by ultrasound or HSG);
  • Patients with a history of recurrent miscarriage (2 or more previous pregnancy losses, excluding biochemical pregnancies);
  • Patients who plan to freeze whole embryos and are unable to complete a single embryo transfer within six months;
See the full eligibility criteria
Who can join
  • Female: age ≥20 and ≤40 years, male: age ≥20 and ≤50 years;
  • Proposed 1st or 2nd cycle of IVF or ICSI fertilization;
  • ≥ 4 transferable embryos at oocyte stage.
What rules you out
  • Diagnosis of abnormal uterine cavity morphology (confirmed by 3D ultrasound or hysteroscopy), including uterine malformations (mediastinal uterus, unicornuate uterus, bicornuate uterus), submucosal uterine fibroids, or...
  • Patients who are proposed to undergo IVM;
  • Patients who are proposed to undergo PGD/ PGS;
  • Patients with untreated severe hydrosalpinx (confirmed by ultrasound or HSG);
  • Patients with a history of recurrent miscarriage (2 or more previous pregnancy losses, excluding biochemical pregnancies);
  • Patients who plan to freeze whole embryos and are unable to complete a single embryo transfer within six months;
  • Patients with contraindications to assisted reproductive technology and pregnancy, or suffering from diseases that have a definite effect on pregnancy: including uncontrolled hypertension, heart disease with definite...

The study team makes the final eligibility decision.

Where it is enrolling

  • Zhengzhou, Henan, China
  • Changzhou, Jiangsu, China
  • Nanjing, Jiangsu, China
  • Suzhou, Jiangsu, China
  • Xi’an, Shanxi, China

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling female, 20 years to 40 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Zhengzhou, Henan, China; Changzhou, Jiangsu, China; Nanjing, Jiangsu, China; Suzhou, Jiangsu, China; Xi’an, Shanxi, China. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.